Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LND101 FMT + ICB in Advanced Melanoma
NCT06623461Phase 2Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of LND101 in melanoma, sponsored by Canadian Cancer Trials Group. Started Apr 2025; status: recruiting.
02
Drugs
LND101
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06623461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623461.